Inhibition of SENP1 induces radiosensitization in lung cancer cells

Wang,Ruo‑Tian; Zhi,Xiu‑Yi; Zhang,Yi; Zhang,Jian

doi:10.3892/etm.2013.1259

Inhibition of SENP1 induces radiosensitization in lung cancer cells

Authors:
- Ruo‑Tian Wang
- Xiu‑Yi Zhi
- Yi Zhang
- Jian Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, Xuanwu Hospital of Capital Medical University (CMU), Beijing 100053, P.R. China
Published online on: August 8, 2013 https://doi.org/10.3892/etm.2013.1259
Pages: 1054-1058

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common and lethal types of malignancy. To date, radiotherapy and chemotherapy have been used as the two major treatment methods. However, radioresistance of lung cancer remains a therapeutic hindrance. The aim of this study was to identify whether small ubiquitin‑related modifier (SUMO)-specific protease 1 (SENP1) is a marker of radioresistance that may serve as a target for enhancing the efficacy of lung carcinoma radiotherapy. SENP1 was observed to be overexpressed in lung cancer tissues, and the modulation of SENP1 expression was demonstrated to significantly affect the proliferation of lung cancer cells. Moreover, silencing the expression of SENP1 using small interfering RNA (siRNA) significantly sensitized lung cancer cells to radiation. Mechanically, it was demonstrated that SENP1 depletion significantly enhanced ionizing radiation (IR)‑induced cell cycle arrest, γ‑H2AX expression and apoptosis. Thus, these data suggest that SENP1 may be a desirable drug target for lung carcinoma radiotherapy.

View Figures

View References

1.	Sculier JP: Nonsmall cell lung cancer. Eur Respir Rev. 22:33–36. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Saadeddin A: Radiotherapy for NSCLC: review of conventional and new treatment techniques. J Infect Public Health. 5(Suppl 1): S45–S49. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Hennon MW and Yendamuri S: Advances in lung cancer surgery. J Carcinog. 11:212012. View Article : Google Scholar
4.	Nadkar A, Pungaliya C, Drake K, et al: Therapeutic resistance in lung cancer. Expert Opin Drug Metab Toxicol. 2:753–777. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Ryan JL: Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol. 132:985–993. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Verger A, Perdomo J and Crossley M: Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 4:137–142. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Wang Y and Dasso M: SUMOylation and deSUMOylation at a glance. J Cell Sci. 122:4249–4252. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Yeh ET: SUMOylation and De-SUMOylation: wrestling with life’s processes. J Biol Chem. 284:8223–8227. 2009.PubMed/NCBI
9.	Bawa-Khalfe T and Yeh ET: SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer. 1:748–752. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Cheng J, Kang X, Zhang S and Yeh ET: SUMO-specific protease 1 is essential for stabilization of HIF1α during hypoxia. Cell. 131:584–595. 2007.PubMed/NCBI
11.	Yu L, Ji W, Zhang H, et al: SENP1-mediated GATA1 deSUMOylation is critical for definitive erythropoiesis. J Exp Med. 207:1183–1195. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM and Yeh ET: SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 285:25859–25866. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Bettermann K, Benesch M, Weis S and Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett. 316:113–125. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Qiao Z, Wang W, Wang L, et al: Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett. 21:6389–6392. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Chen Y, Wen D, Huang Z, et al: 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Hanai K, Babazono T, Nyumura I, et al: Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy. Clin Exp Nephrol. 14:132–136. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Taneja N, Davis M, Choy JS, et al: Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 279:2273–2280. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Xu Y, Li J, Zuo Y, et al: SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. Cancer Lett. 309:78–84. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Li X, Lee YK, Jeng JC, et al: Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem. 282:36177–36189. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Yang Y, Fu W, Chen J, et al: SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 9:1253–1262. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Lindberg MJ, Popko-Scibor AE, Hansson ML and Wallberg AE: SUMO modification regulates the transcriptional activity of MAML1. FASEB J. 24:2396–2404. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Van Nguyen T, Angkasekwinai P, Dou H, et al: SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell. 45:210–221. 2012.PubMed/NCBI